SY002 focuses on an undisclosed target X, a critical enzyme in DNA damage repair. The expression of X is scarce in normal cells, while is overexpressed in tumor cells. X shows synthetic lethality with BRCA1/2 mutations or homologous recombination defects.
Genomic instability is a hallmark of cancer cells, which is largely caused by DNA damage repair defects. Targeting DNA damage repair pathways increases additional burdens to cancer cells and induces cancer cell lethality. This precision targeting strategy is called synthetic lethality.